Guggenheim raises Travere Therapeutics stock price target on FSGS approval

Guggenheim raised its price target on Travere Therapeutics to $56 from $54 and reiterated a Buy rating, implying about 37% upside from the $40.82 share price. The firm’s updated Filspari model, following FDA approval for FSGS, now estimates roughly $2.2 billion in U.S. peak FSGS revenue in 2032 and about $3.1 billion for the combined Filspari franchise. The stock has already rallied 131.5% over the past year and is trading near its 52-week high of $43.31.

Analysis

TVTX is transitioning from a binary regulatory story into a duration story: the market is now pricing a multi-year exclusivity window and a much larger treatable population, which matters more than the latest target revision. The key second-order effect is that launch quality and persistence will drive valuation more than headline approval, because in rare disease franchises the discount rate collapses only after reimbursement, specialist adoption, and repeat dosing data all de-risk execution.

The broader label is the real option value. It expands the addressable pool and, more importantly, makes the franchise less dependent on any single subtype, which should improve payer negotiability and reduce the probability of a one-trial narrative break. That said, consensus is probably underestimating how quickly competitors, payers, and treatment guidelines will respond if utilization ramps faster than expected; when a rare-disease drug starts looking like a billion-dollar product, the scrutiny shifts from science to access and durability.

Near term, the stock is likely to trade on launch metrics over the next 1-3 quarters: prescription momentum, REMS/payer friction, and whether the pediatric expansion adds incremental demand or just shifts timing. The main tail risk is that label breadth does not translate into broad clinical adoption if nephrology specialists remain conservative on who is truly eligible; in that case the equity could de-rate even with good approval headlines. Longer term, the most important upside catalyst is exclusivity extension, because each incremental year should disproportionately expand DCF if peak sales are real and the asset becomes the anchor of the franchise.

Key Decisions for Investors

• Stay long TVTX on a 3-6 month horizon; the setup favors continued multiple expansion if launch data confirm rapid uptake. Risk/reward remains attractive into pullbacks below the recent highs, with upside tied to execution rather than further regulatory news.
• Use TVTX calls or call spreads into the next 1-2 earnings/launch updates to express upside while capping downside from payer friction. Preferred structure: 6-9 month call spreads to monetize volatility compression after the approval-driven move.
• Pair long TVTX vs a basket of unprofitable biotech names with weaker commercial visibility. The trade isolates execution-quality rerating in a post-approval launch story versus names still dependent on binary catalysts.
• Reduce or avoid chasing on strength if prescription data do not appear within the next quarter; the first meaningful reversal likely comes from weak access metrics, not clinical concerns. If initial uptake disappoints, expect a sharp de-rating over 1-2 reporting cycles.
• For holders, treat any evidence of exclusivity extension as a long-dated convexity event and add on confirmation. Each year of added protection can justify materially higher DCF, so the real upside is likely a slower-burn re-rate rather than a one-day pop.